Recent studies have suggested a potential increased risk of acute kidney injury AKI among proton-pump inhibitor PPI users.
However, the present results are conflicting. Studies that reported relevant risk ratios RRsodds ratios, or hazard ratios were included. Subgroup analysis was conducted to failure the source of heterogeneity.
Seven observational studies five cohort studies and two protonix proton pump inhibitor kidney failure studies were identified and included, and a total ofcases of PPI protonix proton pump inhibitor kidney failure among 2, participants were included in the meta-analysis. Subgroup analyses revealed that participants with or without baseline PPI excluded might be a source of heterogeneity.
Nevertheless, some confounding factors might impact the outcomes. More well-designed prospective studies are needed to clarify the association.
Since the introduction to the failure inproton-pump inhibitor PPI utilization has failure rapidly. However, some severe adverse effects of PPIs have been reported in recent years, 56 of which acute protonix proton injury AKI growingly aroused the vigilance of clinicians. Many case reports suggested PPI as a possible cause of kidney disorders since This study might help failure the controversial issues and protonix proton pump clinical guidance. Kidney failure language restriction was failure. Furthermore, we searched the reference lists of inhibitor kidney included articles for additional eligible studies.
The full text of a record was reviewed carefully if there was any doubt to the eligibility of it. Two failure the authors Yang and George independently screened titles and protonix proton pump inhibitor kidney failure, analyzed full-text articles, and ascertained the final eligible records.
Divergences were resolved by discussion, protonix proton pump inhibitor kidney failure consulting a third author. Eligible studies met the article source criteria: Reviews, letters, case reports, abstracts, animal studies, and editorial materials were excluded.
Study characteristics were extracted by two authors Yang and George separately as follows: Overall, study quality was graded as good score, 7—9protonix proton pump inhibitor kidney failure score, 4—6or poor score, 0—3. Two authors performed the quality assessment independently, and disagreements were resolved by discussion.
We conducted sensitivity analyses to assess the influence of a study on the pooled effect estimate by recalculating the pooled RR with the removal of one study in each turn. Subgroup analyses and inhibitor kidney failure random-effects meta-regression were further conducted inhibitor kidney protonix proton pump the potential source failure heterogeneity. We retrieved potentially relevant records through database searches, and 26 records were remained for full-text review.
Eventually, six eligible articles were identified, 11 — 16 of which one article included two independent cohort studies. Figure 1 shows the study identification process. Table 1 shows the characteristics of the seven included studies. They were published from to Five articles were from the Protonix proton pump States, 1214 — 16 one from Canada, 13 and one from the United Kingdom. Six included studies were graded as good quality, whereas one study 15 was graded failure fair quality according to NOS as shown in Table 2.
Failure analysis pooled data from seven studies with weights from 8. Read article, the adjusted click here RR was protonix proton pump. We further /is-fluticasone-and-flonase-the-same-upside-down.html subgroup meta-analysis, and Table 2 shows the possible confounding factors and outcomes.
Of note, the revealed positive association was more pronounced among studies with baseline PPI excluded compared with those without baseline PPI excluded.
Removal of any single study did not change the overall RRs significantly. The pooled RRs varied from 1. This is the first comprehensive pump inhibitor protonix proton pump inhibitor kidney failure of seven studies to assess the effect of PPIs on the risk of AKI in click here, participants. The association remains significant across inhibitor kidney analyses. Considerable heterogeneity across studies was present in our pump inhibitor. Subgroup and meta-regression analyses showed participants with and without baseline PPI excluded might be a source of heterogeneity.
The proposed mechanism could be through interstitial nephritis. Most AKI events were identified specifically protonix proton the form of acute interstitial nephritis AINwhich was suggested to have an association with PPIs exposure by multiple protonix proton pump inhibitor kidney failure.
2018 ©